New promising β-lactamase inhibitors for clinical use

[1]  M. Page,et al.  Cautious Optimism for the Antibacterial Pipeline: Despite dire warnings, there is resurgent effort to develop novel antibiotics, with several dozen candidate drugs already entered into clinical trials , 2014 .

[2]  A. Sundsfjord,et al.  Extended-spectrum beta-lactamase-producing bacteria are not detected in supragingival plaque samples from human fecal carriers of ESBL-producing Enterobacteriaceae , 2014, Journal of oral microbiology.

[3]  R. Bonomo,et al.  New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World , 2013, Antimicrobial Agents and Chemotherapy.

[4]  R. Bonomo,et al.  Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance , 2013, Front. Microbiol..

[5]  Xiangdong Gao,et al.  β-Lactamase inhibitors: an update. , 2013, Mini reviews in medicinal chemistry.

[6]  J. Buynak.  β-Lactamase inhibitors: a review of the patent literature (2010 – 2013) , 2013, Expert opinion on therapeutic patents.

[7]  D. Livermore,et al.  Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. , 2013, The Journal of antimicrobial chemotherapy.

[8]  E. Goldstein,et al.  Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds. , 2013, Diagnostic microbiology and infectious disease.

[9]  E. Goldstein,et al.  In Vitro Activity of Biapenem plus RPX7009, a Carbapenem Combined with a Serine β-Lactamase Inhibitor, against Anaerobic Bacteria , 2013, Antimicrobial Agents and Chemotherapy.

[10]  S. Mangani,et al.  Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases , 2013, Antimicrobial Agents and Chemotherapy.

[11]  J. Karlowsky,et al.  Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination , 2013, Drugs.

[12]  T. Palzkill.  Metallo‐β‐lactamase structure and function , 2013, Annals of the New York Academy of Sciences.

[13]  D. Ehmann,et al.  Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor , 2012, Proceedings of the National Academy of Sciences.

[14]  K. Coleman.  Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. , 2011, Current opinion in microbiology.

[15]  M. Panunzio,et al.  Current trends in β-lactam based β-lactamases inhibitors. , 2011, Current medicinal chemistry.

[16]  N. Woodford,et al.  Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing Enterobacteriaceae , 2010, Antimicrobial Agents and Chemotherapy.

[17]  D. Livermore,et al.  In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. , 2010, The Journal of antimicrobial chemotherapy.

[18]  J. Hermes,et al.  Side chain SAR of bicyclic beta-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem. , 2010, Bioorganic & medicinal chemistry letters.

[19]  R. Bonomo,et al.  Three Decades of β-Lactamase Inhibitors , 2010, Clinical Microbiology Reviews.

[20]  G. Jacoby,et al.  Updated Functional Classification of β-Lactamases , 2009, Antimicrobial Agents and Chemotherapy.

[21]  B. Shoichet,et al.  Structure-based optimization of cephalothin-analogue boronic acids as beta-lactamase inhibitors. , 2008, Bioorganic & medicinal chemistry.

[22]  Robert A. Bonomo,et al.  Extended-Spectrum (cid:2) -Lactamases: a Clinical Update , 2005 .

[23]  P. Bradford.  Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat , 2001, Clinical Microbiology Reviews.

[24]  D. Livermore.  beta-Lactamases in laboratory and clinical resistance , 1995, Clinical microbiology reviews.

[25]  G. Jacoby,et al.  A functional classification scheme for beta-lactamases and its correlation with molecular structure , 1995, Antimicrobial agents and chemotherapy.

[26]  R. Ambler,et al.  The structure of beta-lactamases. , 1980, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[27]  Z. Sekawi,et al.  Extended Spectrum Beta-lactamases: Definition, Classification and Epidemiology. , 2015, Current issues in molecular biology.

[28]  T. Keating,et al.  New antibacterial agents: patent applications published in 2011. , 2014, Pharmaceutical patent analyst.

[29]  S. Tyski,et al.  Looking for the new preparations for antibacterial therapy. II. Clinical trials; new beta-lactam antibiotics and beta-lactamase inhibitors. , 2013, Przeglad epidemiologiczny.